PanGen Biotech, Inc.

As of June 30, 2026, PanGen Biotech, Inc. carries a market capitalization of 65.18B, placing it among publicly traded companies globally. Its enterprise value stands at 53.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PanGen Biotech, Inc. has 13.49M shares outstanding.

As of June 30, 2026, PanGen Biotech, Inc. trades at a trailing price-to-earnings ratio of 60.31. The price-to-sales ratio is 4.82, and the price-to-book ratio stands at 2.12.

As of June 30, 2026, PanGen Biotech, Inc. trades at an EV/EBITDA multiple of 30.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 225.74 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 53.13B versus a market cap of 65.18B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PanGen Biotech, Inc. maintains a current ratio of 9.55, meaning it holds 9.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 14.10 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PanGen Biotech, Inc. posted a return on equity (ROE) of 3.76, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.77 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.23, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.11, useful for judging operating efficiency across full business cycles. The company generates approximately 183.52M in revenue per employee across its workforce of 77.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times PanGen Biotech, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PanGen Biotech, Inc. recorded 2.91M in income tax expense. That works out to an effective tax rate of 0.26, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.14B, leaving 1.13B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, PanGen Biotech, Inc.'s stock has declined approximately 22.87% over the past 52 weeks. The 50-day moving average sits at 4,849.90, while the 200-day moving average is 5,138.28.

Over the twelve months ended June 30, 2026, PanGen Biotech, Inc. generated 14.18B in revenue and converted that into 1.13B in net income, yielding earnings per share of 79.82. EBITDA reached 1.77B, while operating income came in at 235.37M.

As of June 30, 2026, PanGen Biotech, Inc. holds 12.05B in cash and equivalents against 7.39M in total debt, resulting in a net debt position of -3.01B. Total book value stands at 30.75B, with working capital of 21.31B providing operational flexibility.

PanGen Biotech, Inc. produced -2.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.07B in capital expenditures, free cash flow totaled -3.63B - equivalent to -256.78 per share.

Over the twelve months ended June 30, 2026, PanGen Biotech, Inc. posted a gross margin of 28.20, reflecting its pricing power and cost economics. The operating margin of 1.66 and net profit margin of 7.99 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.30: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PanGen Biotech, Inc. shareholders.

As of June 30, 2026, PanGen Biotech, Inc. has an Altman Z-Score of 17.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.